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We discuss the functional roles of β2-adrenergic receptors in skeletal muscle hypertrophy and atrophy as well as the adaptive
responses of β2-adrenergic receptor expression to anabolic and catabolic conditions. β2-Adrenergic receptor stimulation using
anabolicdrugsincreasesmusclemassbypromotingmuscleproteinsynthesisand/orattenuatingproteindegradation.Theseeﬀects
are prevented by the downregulation of the receptor. Endurance training improves oxidative performance partly by increasing β2-
adrenergic receptor density in exercise-recruited slow-twitch muscles. However, excessive stimulation of β2-adrenergic receptors
negatestheirbeneﬁcialeﬀects.Althoughthepreventiveeﬀectsofβ2-adrenergicreceptorstimulationonatrophyinducedbymuscle
disuse and catabolic hormones or drugs are observed, these catabolic conditions decrease β2-adrenergic receptor expression in
slow-twitch muscles. These ﬁndings present evidence against the use of β2-adrenergic agonists in therapy for muscle wasting and
weakness. Thus, β2-adrenergic receptors in the skeletal muscles play an important physiological role in the regulation of protein
and energy balance.
1.Introduction
Theskeletalmuscleisthemostabundanttissueinthehuman
body comprising 40–50% of body mass. Skeletal muscle
protein undergoes rapid turnover, which is regulated by the
balance between the rates of protein synthesis and degra-
dation. Physical activity (exercise training) and anabolic
hormonesanddrugs(sportsdoping)increasemuscleprotein
content. However, sarcopenia and muscle disuse (due to
unloading, microgravity, or inactivity) and diseases decrease
muscle protein content. The rate of protein synthesis is at
least in part mediated by β2-adrenergic receptors (β2-ARs) in
skeletal muscles in both anabolic and catabolic conditions.
ARs belong to the guanine nucleotide-binding G-pro-
tein-coupled receptor (GPCR) family. Skeletal muscle con-
tains a signiﬁcant proportion of β-ARs. The β2 subtype is the
most abundant, while ∼7–10% of ARs are the β1 subtype
[1, 2]. Furthermore, β2-AR is more dense in slow-twitch
muscles than in fast-twitch muscles [3, 4]. However, the
magnitude of anabolic responses to β2-adrenergic agonists
is greater in fast-twitch muscles than in slow-twitch muscles
[5–8].
The family of β-ARs was originally believed to signal
predominantly via coupling with a stimulatory guanine
nucleotide-binding protein, Gαs;h o w e v e r ,r e c e n ts t u d i e s
revealed that both β2-a n dβ3-ARs in skeletal muscle
are also capable of coupling to an inhibitory guanine
nucleotide-binding protein, Gαi [9]. β2-AR activates the
Gαs/adenylyl cyclase (AC)/cyclic adenosine monophosphate
(cAMP)/cAMP-dependent protein kinase A (PKA) signaling2 Journal of Biomedicine and Biotechnology
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Figure 1: Changes in β2-AR expression in hypertrophied and atrophied skeletal muscles. (a) β2-AR stimulation using anabolic drugs
downregulates β2-AR expression in hypertrophied fast-twitch muscles but not in slow-twitch muscles [4, 7, 8, 14–17]. (b) Exercise training
such as endurance training upregulates β2-AR expression in exercise-recruited slow-twitch muscles, whereas no changes or downregulations
a r eo b s e r v e di nf a s t - t w i t c hm u s c l e s[ 18, 19], although muscle mass is not altered. However, although exercise training such as isometric
strength training induces muscle hypertrophy, there is no insight regarding the eﬀects of such exercise on β2-AR expression. The diﬀerential
eﬀects of types of exercise training on physiological responses such as β2-AR expression and muscle hypertrophy should be clariﬁed in more
detailed and are currently being investigated by our group. (c) Catabolic hormones or drugs such as glucocorticoids downregulate β2-AR
expression in nonatrophied slow-twitch muscles but not fast-twitch muscles [16, 20, 21]. (d) Muscle disuse downregulates β2-AR expression
in atrophied slow-twitch muscle, whereas no changes or upregulation of receptor expression are observed in fast-twitch muscles [14, 22].
Up arrow (open arrow): upregulation of β2-AR expression; down arrow (ﬁlled arrow): downregulation of β2-AR expression; lateral arrow
(shade arrow): no change.
pathway. The signaling pathway is at least in part responsible
for the anabolic response of skeletal muscle to β2-AR
stimulation. Further, in addition to the well-documented
inhibition of AC activity [10], β2-AR coupling to Gαi
activates Gαs-independent pathways [11].
β2-AR has 7 transmembrane α helices forming 3 extra-
cellular loops, including an NH2 terminus and 3 intracellular
loops that include a COOH terminus [12]. β2-AR contains
phosphorylation sites in the third intracellular loop and
proximal cytoplasmic tail. Phosphorylation of these sites
triggers the agonist-promoted desensitization, internaliza-
tion, and degradation of the receptor [13]. These regulatory
mechanisms contribute to maintaining agonist-induced β2-
AR responsiveness in various conditions.
The adaptive responses of β2-AR expression to anabolic
and catabolic conditions in skeletal muscles are shown in
Figure 1. Understanding the correlation between changes in
muscle mass and β2-AR expression in several anabolic or
catabolic conditions present scientiﬁc evidence to eradicate
sports doping and identify novel approaches for attenuatingJournal of Biomedicine and Biotechnology 3
muscle atrophy concomitant with disuse and various dis-
eases. This paper will discuss the eﬀects of (1) pharmaco-
logical β2-AR stimulation (sports doping), (2) muscle hyper-
trophy (exercise training), and (3) muscle atrophy (catabolic
conditions and hormones) on β2-AR expression in skeletal
muscles.
2. Pharmacological Stimulation of β2-AR
2.1. Muscle Hypertrophy and β2-AR. A β2-adrenergic ago-
nist, clenbuterol [1-(4-amino-3,5-dichlorobenzyl)-2-(tert-
butylamino) ethanol], is used as a nonsteroidal anabolic
drug for sports doping. According to the recent World Anti-
Doping Agency (WADA) documents, clenbuterol was the
seventh most commonly used anabolic agent in 2009 (67
cases; 2.0% of all anabolic agents used).
Numerous studies have shown that the administration of
β2-adrenergic agonists induces muscle hypertrophy in many
species [23–25]. Experiments using mice lacking β1-AR,
β2-AR, or both demonstrate that β2-adrenergic agonist-
induced functions such as muscle hypertrophy are mediated
by β2-AR [26]. β2-Adrenergic agonists promote muscle
growth by increasing the rate of protein synthesis and/or
decreasing protein degradation [23–25]. Furthermore,
β2-adrenergic agonists induce slow-to-fast [myosin heavy
chain (MHC)I/β → MHCIIa → MHCIId/x → MHCIIb]
transformation of muscle ﬁbers.
The β2-AR signaling pathway involves the agonist-
dependent activation of Gαs, which in turn activates AC,
resulting in increased cAMP production. Cyclic AMP-
activatedPKAinitiatesthetranscriptionofmanytargetgenes
via the phosphorylation of cAMP-response-element-(CRE-)
binding protein (CREB) or adaptor proteins such as CREB-
binding protein (CBP) and p300, subsequently promoting
protein synthesis [23]. While β2-AR-mediated signaling was
traditionally believed to involve selective coupling to Gαs,
recent studies revealed that β2-AR exhibits dual coupling to
both Gαs and Gαi in skeletal muscles [9, 23]. In addition
to Gαs,G αi-linked Gβγ subunits play an active role in
various cell signaling processes such as the phosphoinositol 3
kinase (PI3K)/protein kinase B (Akt)/mammalian target of
rapamycin (mTOR)/p70S6K and PI3K/Akt/forkhead box-O
(FOXO) pathways. These signaling pathways play important
roles in β2-adrenergic agonist-induced hypertrophy in skele-
tal muscles [23].
In addition to promoting protein synthesis, the hyper-
trophic response of skeletal muscles following β2-adrenergic
agonist administration is associated with decreased protein
degradation.β2-Adrenergicagonistsattenuateproteindegra-
dation predominantly via Ca2+-dependent proteolysis and
the ATP/ubiquitin-dependent pathway [27–31]. However,
there is little knowledge regarding the preventive eﬀects of
β2-adrenergic agonists on the proteolysis system compared
with the protein synthesis system.
The hypertrophic responses to β2-adrenergic agonists
are observed much frequently in fast-twitch muscle than in
slow-twitchmuscle.Ourgrouppreviouslydemonstratedthat
clenbuterol administration (1.0mg·kg−1·day−1)t or a t sf o r
10 days increases the mass of fast-twitch (extensor digito-
rum longus: EDL) muscle without altering in slow-twitch
(soleus) muscle [7, 8]; other groups also observed the same
tendency [5, 6, 32–35]. However, the mechanisms of the
ﬁber-type-dependent eﬀects of β2-adrenergic agonists on
muscle hypertrophy remain unclear.
Pearen et al. [36, 37] and Kawasaki et al. [38] identiﬁed
that β2-AR activation increases the expression of the orphan
nuclear receptor, NOR-1 (NR4A3), a negative regulatory
factor of myostatin (a member of the transforming growth
factor-β superfamily and a potent negative regulator of
muscle mass), in fast-twitch muscles without altering that
in slow-twitch muscles. Furthermore, Shi et al. [32]d e m o n -
strate the possibility that β2-adrenergic agonist-induced
ﬁber-type-dependenthypertrophyisinpartduetotheextra-
cellular signal-regulated kinase (ERK)/mitogen activated
protein kinase (MAPK) pathway. Moreover, the pharmaco-
logical inhibition of the PI3K/Akt/mTOR signaling pathway
revealed that the attenuation of the anabolic response to
clenbuterol is greater in fast-twitch muscles than in slow-
twitch muscles [30]. In addition to the protein synthesis
system, Yimlamai et al. [35] found that clenbuterol inhibits
ubiquitination more strongly in fast-twitch muscles than in
slow-twitch muscles. Thus, β2-AR-mediated signaling path-
w a y st e n dt op r o m o t em u s c l eh yp e rt r o p h yt oag r e a t e re x t e n t
in fast-twitch muscle than in slow-twitch muscle.
2.2. Posttranslational Regulation of β2-AR. As shown in
Table 1, some reports focus on the responses of β2-AR
expression to β2-AR stimulation in skeletal muscles [4, 7,
8, 14–17]. This is because β2- A Rf u n c t i o n ss u c ha sm u s c l e
hypertrophy are maintained via receptor density, including
synthesis and downregulation as well as receptor sensitivity,
which includes receptor sensitization, desensitization, phos-
phorylation, and internalization [13, 39, 40].
The desensitization of β2-AR is associated with receptor
phosphorylation. McCormick et al. [41] demonstrate that
fast-twitch ﬁbers mainly express nonphosphorylated β2-AR,
whereas slow-twitch ﬁbers predominantly express phospho-
rylated β2-AR. Furthermore, treating muscle ﬁbers with β2-
adrenergic agonists (e.g., clenbuterol, formoterol, and salbu-
tamol) increases the phosphorylation of β2-AR in slow-
twitch ﬁbers but not in fast-twitch ﬁbers [41]. On the other
hand, the receptor phosphorylation occurs via the actions of
protein kinases (such as PKA) and/or GPCR kinase (GRK).
Rat skeletal muscles contain predominantly GRK2 and
GRK5; GRK protein is expressed more in fast-twitch muscles
than in slow-twitch muscles. These expression levels in each
type of muscle ﬁber are not altered by β2-adrenergic agonist
administration [42]. Thus, there is a negative correlation
between the level of phosphorylated β2-AR and receptor
kinase. Therefore, further investigation is needed to reveal
the detailed mechanism of β2-AR phosphorylation.
Following β2-AR phosphorylation, the receptor is inter-
nalized into the cytosol. The internalized β2-AR is then
degraded or dephosphorylated and subsequently recycled to
the membrane [13, 43–45]. Prolonged administration of β2-
adrenergic agonists leads to the downregulation of β2-AR
density in skeletal muscles [15–17]. These posttranslational4 Journal of Biomedicine and Biotechnology
Table 1: Responses of β2-AR expression in skeletal muscle to anabolic and catabolic conditions.
Conditions Species β2-AR Other ﬁndings References
Protein mRNA
β2-AR stimulation
Fenoterol Rat
↓ (FT) n.d.
[4]
(1.4mg ·kg
−1 ·day
−1,4w e e k s ) →(ST)
Clenbuterol Rat n.d. ↓ (FT) β1-AR mRNA ↓ (LV)
[7]
(1.0mg ·kg
−1 ·day
−1,1 0d a y s ) → (ST) β2-AR mRNA ↓ (LV)
Clenbuterol
Rat
n.d. ↓ (FT) GR mRNA ↓ (FT)
[8]
(1.0mg ·kg
−1 ·day
−1,1 0d a y s ) → (ST) HuR mRNA ↓ (FT)
AUF1 mRNA ↓ (FT)
hnRNP A1 mRNA ↓ (FT)
Fenoterol Rat
→ (FT, ST) ↓ (FT, ST) Gαs content→(FT, ST)
[14]
(1.4mg ·kg
−1 ·day
−1, 2–7 days) AC activity→ (FT, ST)
Clenbuterol Rat
↓ (FT+ST) n.d.
[15]
(2.0mg ·kg
−1 ·day
−1,1 8d a y s )
Clenbuterol Rat
↓ (FT) n.d. β2-AR aﬃnity→ (FT)
[16]
(4.0mg ·kg
−1 of feed, 10 days)
Clenbuterol Rat
↓ (FT+ST) n.d.
[17]
(0.2mg ·kg
−1 ·day
−1, 7 days)
Clenbuterol (50μM)
Mouse (ex vivo)
Phosphorylated n.d. cAMP concentration ↑
[41]
Formoterol (100μM) β2-AR ↑ (ST), (FT, ST)
Salbutamol (500μM) →(FT)
Endurance training
Treadmill (12 weeks)
Rat
↓ (FT) n.d. β2-AR aﬄnity →
[18]
AC activty ↓
Gαs content ↓
Treadmill (18 weeks) Rat
→ (FT) n.d. AC activity ↑ (FT, ST)
[19]
↑ (ST) β2-AR density→(acute)
Catabolic conditions
Dexamethasone
Rat
→ (FT, ST) → (FT) GR mRNA ↓ (FT, ST)
[20]
(1.0mg ·kg
−1 ·day
−1,1 0d a y s ) ↓ (ST) CREB mRNA ↓ (ST)
AUF1 mRNA ↑(FT)
Dexamethasone Rat n.d. → (FT) GR mRNA ↓ (FT, ST)
[21]
(1.0mg ·kg
−1 ·day
−1,1 0d a y s ) ↓ (ST) β1-AR mRNA ↑ (LV)
Dexamethasone Rat
→ (FT) n.d. β2-AR aﬃnity→(FT)
[16]
(0.2mg ·kg
−1 ·day
−1,1 0d a y s )
Casted-immobilization Rat
→ (FT, ST) → (FT) GR mRNA ↓ (ST)
[22]
(10 days) ↓ (ST) GR protein ↓ (ST)
Aging Rat → (FT, ST) n.d. [4]
Injury Rat
↑ (FT) ↑ (FT) Gαs content ↑ (FT), ↓ (ST)
[14]
(bupivacaine injection) ↓ (ST) ↓ (ST) AC activity ↑ (FT, ST)
FT, fast-twitch muscle; ST, slow-twitch muscle; LV, left ventricle muscle. Up arrow, increase; down arrow, decrease; lateral arrow, no change. n.d., no data.
regulations are advantageous for maintaining the rate of
muscle protein synthesis and/or degradation.
2.3. Short-Term and Chronic Transcriptional Regulation of
β2-AR. β2-AR synthesis, including transcription and sub-
sequent translation, is required to restore transmembrane
receptor density. The process of β2-AR synthesis can be
separated into 2 pathways: (1) the positive autoregulation of
β2-AR gene transcription via receptor-mediated elevation of
cAMP concentration followed by the phosphorylation and
activation of CREB [46, 47] and (2) the transactivation of
the β2-AR gene via interaction between hormones and the
nuclear receptor complex and response elements on the β2-
AR promoter region [48]. In particular, the transcription
of the β2-AR gene and the subsequent mRNA expression
via cAMP-mediated CRE activation increased in response to
short-term β2-adrenergic agonist exposure [46, 47]. More-
over, treatment with glucocorticoids or thyroid hormone
transactivates the β2-AR gene both in vitro and in vivo [48–
51].
Our previous reports demonstrate that clenbuterol
administration (1.0mg·kg−1·day−1)f o r1 0d a y st or a t sJournal of Biomedicine and Biotechnology 5
decreases β2-AR mRNA expression in the fast-twitch EDL
musclewithoutalteringthatintheslow-twitchsoleusmuscle
[7, 8]. Furthermore, the mRNA expression of glucocorti-
coid receptors (GRs) was also decreased with clenbuterol
treatment in the EDL muscle but not in the soleus muscle
[8]. Glucocorticoids and the GR complex activate the
transcription of the β2-AR gene via interaction with glu-
cocorticoid response elements (GREs), consensus cis-acting
DNA sequences (i.e., AGA ACA nnn TGT TCT) on its
promoter regions [48], thus upregulating β2-AR expression
[16, 50, 51]. These ﬁndings corroborate our results that
there is a positive correlation between the expression levels
of β2-AR and GR in skeletal muscles. Beitzel et al. [14] also
report that administrating the β-adrenergic agonist, fenot-
erol (1.4mg·kg−1·day−1, i.p.), for 5 days decreases β2-AR
mRNA expression in the EDL and soleus muscles. Thus,
in contrast to the transactivation of the β2-AR gene and
increase in the mRNA level in response to short-term agonist
exposure, chronic β2-adrenergic stimulation inhibits β2-AR
synthesis in skeletal muscles.
2.4. Posttranscriptional Regulation of β2-AR. In addition
to post-translational and transcriptional regulation, several
groups focus on the posttranscriptional regulation of β2-
AR mRNA. β2-AR mRNA contains an AU-rich element
(ARE) within the 3 -untranslated region (3 -UTR) that can
be recognized by several mRNA-binding proteins, including
Hu antigen R (HuR), AU-rich element binding/degradation
factor1 (AUF1), and heterogeneous nuclear ribonucleopro-
tein A1 (hnRNP A1) [52–55] .T h e s ef a c t o r sp l a yar o l ei n
the regulation of β2-AR mRNA stability [52–55]. Our study
demonstrates that clenbuterol-induced stimulation of β2-
AR decreases the mRNA expressions of these factors in the
EDL but not in the soleus muscle [8], suggesting that the
posttranscriptional process of β2-AR synthesis requires the
stability of its mRNA to be regulated.
3. ExerciseTrainingand β2-AR
Strength-resistancetrainingincreasesmusclemass[56],ﬁber
cross-sectional area [57], protein and RNA contents [58],
and the capacity to generate force [59]. In contrast to
strength training, endurance training is characterized by
increased mitochondrial mass [60], increased oxidative
enzymes [61], decreased glycolytic enzymes [62], increased
slow contractile and regulatory proteins [62], and decreased
fast ﬁber area [63]. These ﬁndings suggest that the functional
roles of β2-AR in skeletal muscles diﬀer with the type of
exercise training.
3.1. Strength Exercise Training and β2-AR. Mounier et al.
[64]investigatedthechangesintheweightoftheEDLmuscle
induced by clenbuterol administration, strength training,
and a combination of both. They found that the eﬀects of
strength training and clenbuterol on muscle hypertrophy
were not additive in fast-twitch muscles. Their report
also demonstrates that the strength-training-induced en-
hancement of lactate dehydrogenase-speciﬁc activity is
completely inhibited by clenbuterol administration, while
the clenbuterol-induced decrease in monocarboxylate trans-
porter1 mRNA expression is completely oﬀset by strength
training [64]. Thus, there are no synergetic eﬀects of a
combination of strength training and β2-AR stimulation
on muscle mass. Furthermore, strength training counteracts
molecular modiﬁcations such as glycolytic control induced
by chronic clenbuterol administration in fast-twitch muscles
to some extent. However, our evidence regarding the syn-
ergistic eﬀects of strength training and β2-AR stimulation
is insuﬃcient because the experimental models of strength-
trained animals are not fully established.
3.2. Endurance Exercise Training and β2-AR. In contrast to
strength training, β2-AR stimulation aﬀects endurance-
training-induced modulations such as contractile activity
[65], muscle ﬁber-type shift [65], metabolic enzyme activity
[66], and insulin resistance [67, 68] .L y n c he ta l .[ 65]
demonstratedthatlow-intensityendurancetrainingprevents
clenbuterol-induced slow-to-fast (type I ﬁber → type II
ﬁber) ﬁber-type transformation in the EDL and soleus mus-
cles, and thereby oﬀsets the clenbuterol-induced decrease in
Ca2+ sensitivity in fast-twitch ﬁbers. These results suggest
that endurance-training-heightened muscle aerobic capacity
is attenuated by β2-AR stimulation-induced muscle ﬁber-
type transformations. Furthermore, pharmacological β-
AR blockage diminishes the endurance-training-induced
increase in citrate synthase activity in the fast-twitch
plantaris muscle [66]. Moreover, clenbuterol administra-
tion prevents the endurance-training-induced improvement
in insulin-stimulated glucose uptake and attenuates the
increase in citrate synthase activity in the skeletal muscles
of obese Zucker rats [67, 68]. These ﬁndings demonstrate
that the endurance-training-induced increase in aerobic
metabolism in skeletal muscles requires moderate but not
excessive stimulation of β2-AR.
R e c e n t l y ,M i u r ae ta l .[ 69] demonstrated that an increase
in peroxisome proliferator-activated receptor-γ coactivator-
1α (PGC-1α) mRNA in response to exercise is mediated
by β2-AR activation. Furthermore, the Ca2+-signaling [70]
and p38 MAPK pathways [71], which is downstream of
β2-AR, are activated in skeletal muscles in response to
exercise, which regulates PGC-1α expression. Since PGC-
1α promotes mitochondrial biogenesis [72], the exercise-
induced activation of β2-AR may in part enhance aerobic
capacity by increasing PGC-1α expression. Thus, β2-AR
stimulation is essential for enhancing the eﬀects of exercise
training on muscle functions such as ﬁber-type shift as well
as oxidative and anaerobic metabolism.
3.3. Response of β2-AR Expression to Exercise Training. As
mentioned above, the functional roles of β2-AR during
exercise training are physiologically important in skeletal
muscles. Therefore, changes in the expression and sensitivity
of β2-AR should be important for the metabolic, anabolic,
and catabolic adaptations of skeletal muscles during exercise
training. Nevertheless, there is little information on the
response of β2-AR expression to exercise training in skeletal
muscles. However, many studies demonstrate the eﬀects
of exercise training on β2-AR expression in several tissues6 Journal of Biomedicine and Biotechnology
and cell types such as myocardia [73, 74], adipocytes [75],
and macrophages [76]. Barbier et al. [73] demonstrated
that exercise training induces changes in the distribution
of β1-, β2-, and β3-AR densities in the rat left ventricle. In
adipocytes,theexercise-inducedtraﬃckingofβ2-ARintothe
cell membrane from the cytosol is coupled with adipocytes’
function to increase intracellular cAMP production [75].
Kizaki et al. [76] also found a reduction in the expression of
β2-AR mRNA in macrophages and highlight the signiﬁcance
of β2-AR in the exercise training-induced improvement of
macrophages’ innate immune function. Thus, changes in β2-
AR expression play a role in physiological adaptations to
exercise training in several tissues.
A few studies also report the eﬀects of exercise training
on β-AR in skeletal muscles [18, 19, 77, 78]( Table 1). Nieto
et al. [18] demonstrate that β-AR density and Gαs content in
the fast-twitch gastrocnemius muscle are signiﬁcantly lower
inendurance-exercisedrats thanincontrols.Theyalsoreveal
that exercise reduces receptor- and nonreceptor-mediated
(i.e., pharmacological stimulation of AC by forskolin) AC
activity in muscles [18]. However, Buckenmeyer et al. [19]
report that endurance training increases β-AR density in
slow-twitch muscles that are primarily recruited during
endurance training, whereas β-AR density is not altered
in fast-twitch muscles. Their report also demonstrates that
receptor-mediated AC activity in slow-twitch muscles is
increased by endurance training, and nonreceptor-mediated
AC activity is increased by training in both fast- and
slow-twitch muscles [19]. In contrast to chronic endurance
training, the eﬀects of acute exercise on β-AR density and AC
activityineachtypeofmusclewerenotobserved[19].There-
fore, endurance-exercise-training-induced changes in β2-AR
expression and signaling in slow-twitch muscle contributes
totheadaptationofmetabolicandanaboliccapacitiesduring
exercise.
4. Muscle Atrophy andβ2-AR
4.1. Preventive Roles of β2-AR in Disuse-Induced Muscle
Atrophy. Musclewastingandweaknessarecommoninphys-
iological and pathological conditions, including aging,
cancer cachexia, sepsis, other forms of catabolic stress,
denervation, disuse (e.g., unloading, inactivity, and micro-
gravity), burns, human immunodeﬁciency virus-(HIV)-
acquired immunodeﬁciency syndrome (AIDS), chronic kid-
ney or heart failure, chronic obstructive pulmonary disease
(COPD), and muscular dystrophies. For many of these
conditions, the anabolic properties of β2-adrenergic agonists
provide therapeutic potential for attenuating or reversing
muscle wasting, muscle ﬁber atrophy, and muscle weakness.
These β2-adrenergic agonists also have important clinical
signiﬁcance for enhancing muscle repair and restoring
muscle function after muscle atrophy.
In particular, muscle disuse, which is mainly reﬂected by
increased myoﬁbrillar protein breakdown, causes a progres-
sive decrease in muscle strength associated with a decreased
cross-sectional area of muscle ﬁbers. Therefore, preventing
disuse-inducedmuscleatrophyisaproblemrequiringurgent
attentionandhighlightsβ2-ARasatargetofpharmacological
stimulation. Since 2000, many groups have focused on the
preventive eﬀectsof β2-adrenergicagonistondisuse-induced
muscle atrophy [4, 34, 35, 79].
Yimlamai et al. [35] demonstrate that clenbuterol
attenuates the hindlimb unweighting-induced atrophy and
reducesubiquitinconjugatesonlyinfast-twitchplantarisand
tibialis anterior muscles but not in the slow-twitch soleus
muscle; this suggests that clenbuterol alleviates hindlimb
unweighting-induced atrophy, particularly, in fast-twitch
muscles at least in part through a muscle-speciﬁc inhibition
oftheubiquitin-proteasomepathway.However,Stevensetal.
[34] report that clenbuterol treatment accelerates hindlimb
unweighting-induced slow-to-fast (MHCI/β → MHCIIa →
MHCIId/x → MHCIIb) transformation in the soleus mus-
cle. β2-Adrenergic agonist also reverses muscle wasting and
weakness in several conditions such as aging [4], muscular
dystrophy [29], denervation [80], cancer cachexia [28], and
myotoxic injury [81].
4.2. Preventive Roles of β2-AR in Catabolic Hormone-Induced
Muscle Atrophy. Prolonged muscle disuse and/or unload-
ing increases the secretion of glucocorticoids, which pro-
motes the catabolism of muscle proteins via the ubiquitin-
proteasomepathway[82,83].Sepsisalsoelevatesplasmaglu-
cocorticoids and adrenocorticotropic hormone (ACTH) lev-
els [84]. Therefore, several studies focus on the counteractive
eﬀectsofβ2-ARstimulationonglucocorticoid-inducedmus-
cle atrophy [16, 85]. Huang et al. [16] report that clenbuterol
almost prevents the decrease in the weight of gastrocne-
mius/plantaris muscle bundles induced by dexamethasone,
a synthetic glucocorticoid. Pellegrino et al. [85]d e m o n -
s t r a t et h a tc o n c u r r e n tt r e a t m e n to fc l e n b u t e r o lw i t hd e x -
amethasone minimizes MHC-transformation-induced by
clenbuterol (slow-to-fast) or dexamethasone (fast-to-slow)
alone. Thus, β2-AR stimulation plays an inhibitory role in
muscle atrophy and weakness induced by catabolic diseases,
mechanical unloading, catabolic hormones, and pharmaco-
logical agents.
4.3. Response of β2-AR Expression to Catabolic Hormones.
Although the eﬀectiveness of β2-AR stimulation on muscle
atrophy is well documented, catabolic condition-induced
changes in the expression of β2-AR in skeletal muscles are
not fully understood. Understanding the responses of β2-
AR expression to muscle atrophy is required to establish
treatments for muscle atrophy.
Table 1 shows the catabolic-condition-induced changes
in β2-AR expression in skeletal muscles. Our group inves-
tigated whether catabolic hormones or agents alter β2-AR
expression in skeletal muscles [20, 21]. Dexamethasone
administration (1.0mg·kg−1·day−1)t or a t sf o r1 0d a y s
decreases the expression of β2-AR mRNA in the soleus
musclewithoutalteringthatintheEDLmuscle,althoughthe
expression of β2-AR protein in the EDL and soleus muscles
is not altered [20, 21]. Dexamethasone also does not alter
β2-AR density in gastrocnemius/plantaris muscle bundles
[16]. These phenomena are speciﬁcally observed in skeletalJournal of Biomedicine and Biotechnology 7
muscles; meanwhile, glucocorticoids and the GR complex
activate the transcription of β2-AR gene in the human
hepatomacellline(HepG2)[48],subsequentlyleadingtothe
upregulation of β2-AR levels in DDT1 MF-2 smooth muscle
cells [50] and lung tissue [16, 51]. Furthermore, dexam-
ethasone decreases the expression of GR mRNA in the
soleus muscle [20, 21]. Dexamethasone also decreases and
increases the expression of CREB mRNA, a transcription
factor of the β2-AR gene [46, 47], in the soleus and EDL
muscles, respectively [20]. These ﬁndings suggest that the
dexamethasone-induced decrease in the expression of β2-AR
mRNA in the slow-twitch soleus muscle is associated with
transcriptional regulations.
4.4. Response of β2-AR Expression to Muscle Disuse. The
eﬀectsofphysiologicalandpathologicalcatabolic-condition-
induced muscle atrophy on β2-AR expression have also
been studied (Table 1)[ 4, 14, 22]. Our recent investigation
demonstrates that casted immobilization (knee and foot
arthrodesis) for 10 days markedly induced atrophy in the
soleus muscle, whereas it decreased the expression of β2-AR
mRNA [22]. Decreased GR mRNA and protein expression
was also detected in the soleus muscle [22]. These results
suggest that casted immobilization decreases the expression
of β2-AR mRNA in slow-twitch muscles via the downreg-
ulation of GR levels and subsequent glucocorticoid signals.
On the other hand, Ryall et al. [4] demonstrate that aging-
induced muscle wasting is observed in the EDL and soleus
muscles, although there are no age-associated changes in β2-
AR density in these muscles. Furthermore, in the regener-
ation process from muscle injury induced by bupivacaine
injection,β2-ARdensityandmRNAexpressionaswellasGαs
content are decreased in the soleus but increased in the EDL
muscle [14]. Thus, the eﬀects of catabolic conditions such as
disuse, aging, and injury on β2-AR expression are diﬀerent
from and/or dependent on the conditions, especially in fast-
twitch muscles, whereas decreasing tendencies are observed
in slow-twitch muscles.
Both pharmacological and mechanical studies indicate
that the preventive eﬀects of β2-AR stimulation on muscle
atrophy and weakness are limited by decreased β2-AR syn-
thesisandsubsequentlydecreaseddensity.Inordertouse β2-
adrenergicagonistsasatherapeuticagentformusclewasting,
further studies are necessary to obtain detailed evidence
regarding the responses of β2-AR expression and function to
muscle atrophy.
5. Conclusions
In this paper, we discussed adaptive responses of β2-AR
expression in skeletal muscles to β2-adrenergic agonist treat-
ment, exercise training, muscle disuse, and glucocorticoid
treatment. This paper also outlined the functional roles of
β2-AR in skeletal muscles. Skeletal muscle partly requires
β2-AR activation for hypertrophy, regeneration, and atrophy
prevention; however, its functions and responsiveness must
be adaptively regulated by the receptor itself via downregula-
tion, synthesis, and desensitization. New insight in the form
ofscientiﬁcevidenceisneededtoeradicatesportsdopingand
to identify new therapeutic targets for attenuating muscle
atrophy induced by physiological and pathological condi-
tions.
Acknowledgments
The authors would like to thank Professor Hideki Suzuki,
Department of Health and Physical Education, Aichi Univer-
sity of Education, and Professor Hisaya Tsujimoto, Institute
of Health and Sports Science, Kurume University, for their
valuable advice and suggestions. This work was supported
by Research Fellowships of the Japan Society for Promotion
of Science for Young Scientists (2010–2011: S. Sato) and
a Grant-in-Aid of the Global Center of Excellence (COE)
program,GraduateSchoolofSportSciences,WasedaUniver-
sity (2009–2013: K. Imaizumi) of the Ministry of Education,
Culture, Sports, Science, and Technology, Japan.
References
[ 1 ] Y .S .K i m ,R .D .S a i n z ,P .M o l e n a a r ,a n dR .J .S u m m e r s ,“ C h a r -
acterization of β1-a n dβ2-adrenoceptors in rat skeletal mus-
cles,” Biochemical Pharmacology, vol. 42, no. 9, pp. 1783–1789,
1991.
[2] R. S. Williams, M. G. Caron, and K. Daniel, “Skeletal muscle
β-adrenergic receptors: variations due to ﬁber type and
training,” American Journal of Physiology, vol. 246, no. 2, part
1, pp. E160–E167, 1984.
[ 3 ] J .G .R y a l l ,P .G r e g o r e v i c ,D .R .P l a n t ,M .N .S i l l e n c e ,a n dG .S .
Lynch, “β2-agonist fenoterol has greater eﬀects on contractile
function of rat skeletal muscles than clenbuterol,” American
Journal of Physiology, vol. 283, no. 6, pp. R1386–R1394, 2002.
[ 4 ]J .G .R y a l l ,D .R .P l a n t ,P .G r e g o r e v i c ,M .N .S i l l e n c e ,a n d
G. S. Lynch, “β2-agonist administration reverses muscle
wasting and improves muscle function in aged rats,” Journal
of Physiology, vol. 555, no. 1, pp. 175–188, 2004.
[5] J. G. Burniston, W. A. Clark, L. B. Tan, and D. F. Goldspink,
“Dosedependentseparationofthehypertrophicandmyotoxic
eﬀects of the β2 agonist clenbuterol in rat striated muscles,”
Muscle and Nerve, vol. 33, no. 5, pp. 655–663, 2006.
[ 6 ]J .G .R y a l l ,M .N .S i l l e n c e ,a n dG .S .L y n c h ,“ S y s t e m i c
administration of β2-adrenoceptor agonists, formoterol and
salmeterol, elicit skeletal muscle hypertrophy in rats at micro-
molar doses,” British Journal of Pharmacology, vol. 147, no. 6,
pp. 587–595, 2006.
[7] S. Sato, S. Nomura, F. Kawano, J. Tanihata, K. Tachiyashiki,
and K. Imaizumi, “Eﬀects of the β2-agonist clenbuterol on β1-
andβ2-adrenoceptormRNAexpressionsofratskeletalandleft
ventricle muscles,” Journal of Pharmacological Sciences, vol.
107, no. 4, pp. 393–400, 2008.
[8] S. Sato, S. Nomura, F. Kawano, J. Tanihata, K. Tachiyashiki,
and K. Imaizumi, “Adaptive eﬀects of the β2-agonist clen-
buterol on expression of β2-adrenoceptor mRNA in rat fast-
twitchﬁber-richmuscles,”JournalofPhysiologicalSciences,vol.
60, no. 2, pp. 119–127, 2010.
[9] A. R. Gosmanov, J. A. Wong, and D. B. Thomason, “Duality
of G protein-coupled mechanisms for β-adrenergic activation
of NKCC activity in skeletal muscle,” American Journal of
Physiology, vol. 283, no. 4, pp. C1025–C1032, 2002.
[10] S. N. Abramson, M. W. Martin, A. R. Hughes et al., “Inter-
action of β-adrenergic receptors with the inhibitory guanine8 Journal of Biomedicine and Biotechnology
nucleotide-binding protein of adenylate cyclase in membranes
prepared fromcyc-S49 lymphoma cells,” BiochemicalPharma-
cology, vol. 37, no. 22, pp. 4289–4297, 1988.
[11] C. Communal, W. S. Colucci, and K. Singh, “p38 mitogen-
activated protein kinase pathway protects adult rat ventricular
myocytes against β-adrenergic receptor-stimulated apoptosis.
Evidence for Gi-dependent activation,” Journal of Biological
Chemistry, vol. 275, no. 25, pp. 19395–19400, 2000.
[12] M. Johnson, “Molecular mechanisms of β2-adrenergic recep-
tor function, response, and regulation,” Journal of Allergy and
Clinical Immunology, vol. 117, no. 1, pp. 18–24, 2006.
[13] J. G. Krupnick and J. L. Benovic, “The role of receptor kinases
and arrestins in G protein-coupled receptor regulation,”
Annual Review of Pharmacology and Toxicology, vol. 38, pp.
289–319, 1998.
[14] F. Beitzel, M. N. Sillence, and G. S. Lynch, “β-Adrenoceptor
signaling in regenerating skeletal muscle after β-agonist
administration,” American Journal of Physiology, vol. 293, no.
4, pp. E932–E940, 2007.
[ 1 5 ]N .J .R o t h w e l l ,M .J .S t o c k ,a n dD .K .S u d e r a ,“ C h a n g e si n
tissue blood ﬂow and β-receptor density of skeletal muscle in
rats treated with the β2-adrenoceptor agonist clenbuterol,”
British Journal of Pharmacology, vol. 90, no. 3, pp. 601–607,
1987.
[16] H. Huang, C. Gazzola, G. G. Pegg, and M. N. Sillence, “Diﬀer-
ential eﬀects of dexamethasone and clenbuterol on rat growth
and on β2-adrenoceptors in lung and skeletal muscle,” Journal
of Animal Science, vol. 78, no. 3, pp. 604–608, 2000.
[17] M. N. Sillence, M. L. Matthews, W. G. Spiers, G. G. Pegg, and
D. B. Lindsay, “Eﬀects of clenbuterol, ICI118551 and sotalol
on the growth of cardiac and skeletal muscle and on β2-
adrenoceptor density in female rats,” Naunyn-Schmiedeberg’s
Archives of Pharmacology, vol. 344, no. 4, pp. 449–453, 1991.
[18] J. L. Nieto, I. Diaz-Laviada, J. M. Malpartida, I. Galve-Roperh,
and A. Haro, “Adaptations of the β-adrenoceptor-adenylyl
cyclase system in rat skeletal muscle to endurance physical
training,” Pﬂugers Archiv European Journal of Physiology, vol.
434, no. 6, pp. 809–814, 1997.
[19] P. J. Buckenmeyer, A. H. Goldfarb, J. S. Partilla, M. A. Pineyro,
and E. M. Dax, “Endurance training, not acute exercise, dif-
ferentiallyaltersβ-receptorsandcyclaseinskeletalﬁbertypes,”
American Journal of Physiology, vol. 258, no. 1, pp. E71–E77,
1990.
[20] S. Sato, K. Shirato, K. Tachiyashiki, and K. Imaizumi, “Synthe-
sized glucocorticoid, dexamethasone regulates the expressions
of β2-adrenoceptor and glucocorticoid receptor mRNAs but
not proteins in slow-twitch soleus muscle of rats,” Journal of
Toxicological Sciences, vol. 36, no. 4, pp. 479–486, 2011.
[21] F.Kawano,J.Tanihata,S.Satoetal.,“Eﬀectsofdexamethasone
on the expression of β1-, β2-a n dβ3-adrenoceptor mRNAs
in skeletal and left ventricle muscles in rats,” Journal of
Physiological Sciences, vol. 59, no. 5, pp. 383–390, 2009.
[22] S. Sato, H. Suzuki, H. Tsujimoto, K. Shirato, K. Tachiyashiki,
and K. Imaizumi, “Casted-immobilization downregulates
glucocorticoid receptor expression in rat slow-twitch muscle,”
Life Sciences. in press.
[23] G. S. Lynch and J. G. Ryall, “Role of β-adrenoceptor signaling
in skeletal muscle: implications for muscle wasting and dis-
ease,” Physiological Reviews, vol. 88, no. 2, pp. 729–767, 2008.
[24] J.G.RyallandG.S.Lynch,“Thepotentialandthepitfallsof β-
adrenoceptor agonists for the management of skeletal muscle
wasting,” Pharmacology and Therapeutics, vol. 120, no. 3, pp.
219–232, 2008.
[25] Y. S. Kim and R. D. Sainz, “β-adrenergic agonists and
hypertrophy of skeletal muscles,” Life Sciences, vol. 50, no. 6,
pp. 397–407, 1992.
[ 2 6 ]R .T .H i n k l e ,K .M .B .H o d g e ,D .B .C o d y ,R .J .S h e l d o n ,B .
K. Kobilka, and R. J. Isfort, “Skeletal muscle hypertrophy and
anti-atrophy eﬀects of clenbuterol are mediated by the β2-
adrenergic receptor,” Muscle and Nerve, vol. 25, no. 5, pp. 729–
734, 2002.
[27] P. Costelli, C. Garcia-Martinez, M. Llovera et al., “Muscle
protein waste in tumor-bearing rats is eﬀectively antagonized
by a β2-adrenergic agonist (clenbuterol). Role of the ATP-
ubiquitin-dependent proteolytic pathway,” Journal of Clinical
Investigation, vol. 95, no. 5, pp. 2367–2372, 1995.
[28] S. Busquets, M. T. Figueras, G. Fuster et al., “Anticachectic
eﬀects of formoterol: a drug for potential treatment of muscle
wasting,” Cancer Research, vol. 64, no. 18, pp. 6725–6731,
2004.
[29] L. J. Harcourt, J. D. Schertzer, J. G. Ryall, and G. S. Lynch,
“Low dose formoterol administration improves muscle func-
tion in dystrophic mdx mice without increasing fatigue,”
Neuromuscular Disorders, vol. 17, no. 1, pp. 47–55, 2007.
[30] W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine,
“Rapamycin inhibits the growth and muscle-sparing eﬀects of
clenbuterol,” Journal of Applied Physiology, vol. 102, no. 2, pp.
740–747, 2007.
[31] L. C. C. Navegantes, N. M. Z. Resano, R. H. Migliorini,
and C. Kettelhut, “Catecholamines inhibit Ca2+-dependent
proteolysis in rat skeletal muscle through β2-adrenoceptors
and cAMP,” American Journal of Physiology, vol. 281, no. 3, pp.
E449–E454, 2001.
[32] H. Shi, C. Zeng, A. Ricome, K. M. Hannon, A. L. Grant, and
D. E. Gerrard, “Extracellular signal-regulated kinase pathway
is diﬀerentially involved in β-agonist-induced hypertrophy in
slow and fast muscles,” American Journal of Physiology, vol.
292, no. 5, pp. C1681–C1689, 2007.
[33] T.Kitaura,N.Tsunekawa,andH.Hatta,“Decreasedmonocar-
boxylate transporter 1 in rat soleus and EDL muscles exposed
toclenbuterol,”JournalofAppliedPhysiology,v ol.91,no .1,pp .
85–90, 2001.
[34] L. Stevens, C. Firinga, B. Gohlsch, B. Bastide, Y. Mounier,
and D. Pette, “Eﬀects of unweighting and clenbuterol on
myosin light and heavy chains in fast and slow muscles of rat,”
American Journal of Physiology, vol. 279, no. 5, pp. C1558–
C1563, 2000.
[ 3 5 ] T .Y i m l a m a i ,S .L .D o d d ,S .E .B o r s t ,a n dS .P a r k ,“ C l e n b u t e r o l
induces muscle-speciﬁc attenuationofatrophythrougheﬀects
on the ubiquitin-proteasome pathway,” Journal of Applied
Physiology, vol. 99, no. 1, pp. 71–80, 2005.
[36] M. A. Pearen, J. G. Ryall, M. A. Maxwell, N. Ohkura, G. S.
Lynch, and G. E. O. Muscat, “The orphan nuclear receptor,
NOR-1, is a target of β-adrenergic signaling in skeletal
muscle,” Endocrinology, vol. 147, no. 11, pp. 5217–5227, 2006.
[ 3 7 ]M .A .P e a r e n ,S .A .M y e r s ,S .R a i c h u r ,J .G .R y a l l ,G .S .L y n c h ,
a n dG .E .O .M u s c a t ,“ T h eo r p h a nn u c l e a rr e c e p t o r ,N O R - 1 ,a
target of β-adrenergic signaling, regulates gene expression that
controls oxidative metabolism in skeletal muscle,” Endocrinol-
ogy, vol. 149, no. 6, pp. 2853–2865, 2008.
[38] E. Kawasaki, F. Hokari, M. Sasaki, A. Sakai, K. Koshinaka, and
K. Kawanaka, “The eﬀects of β-adrenergic stimulation and
exercise on NR4A3 protein expression in rat skeletal muscle,”
Journal of Physiological Sciences, vol. 61, no. 1, pp. 1–11, 2010.
[39] K. L. Pierce, R. T. Premont, and R. J. Lefkowitz, “Seven-
transmembrane receptors,” Nature Reviews Molecular Cell
Biology, vol. 3, no. 9, pp. 639–650, 2002.Journal of Biomedicine and Biotechnology 9
[ 4 0 ]A .C l a i n g ,S .A .L a p o r t e ,M .G .C a r o n ,a n dR .J .L e f k o w i t z ,
“Endocytosis of G protein-coupled receptors: roles of G
protein-coupled receptor kinases and ß-arrestin proteins,”
Progress in Neurobiology, vol. 66, no. 2, pp. 61–79, 2002.
[41] C. McCormick, L. Alexandre, J. Thompson, and G. Mutungi,
“Clenbuterol and formoterol decrease force production in
isolated intact mouse skeletal muscle ﬁber bundles through a
β2-adrenoceptor-independent mechanism,” Journal of Applied
Physiology, vol. 109, no. 6, pp. 1716–1727, 2010.
[ 4 2 ]S .W .J o n e s ,D .J .B a k e r ,a n dP .L .G r e e n h a ﬀ, “G protein-
coupled receptor kinases 2 and 5 are diﬀerentially expressed in
rat skeletal muscle and remain unchanged following β2-
agonist administration,” Experimental Physiology, vol. 88, no.
2, pp. 277–284, 2003.
[43] S. M. DeWire, S. Ahn, R. J. Lefkowitz, and S. K. Shenoy, “β-
arrestins and cell signaling,” Annual Review of Physiology, vol.
69, pp. 483–510, 2007.
[44] C. A. C. Moore, S. K. Milano, and J. L. Benovic, “Regulation of
receptor traﬃcking by GRKs and arrestins,” Annual Review of
Physiology, vol. 69, pp. 451–482, 2007.
[45] S. K. Shenoy and R. J. Lefkowitz, “Multifaceted roles of
β-arrestins in the regulation of seven-membrane-spanning
receptor traﬃcking and signalling,” Biochemical Journal, vol.
375, no. 3, pp. 503–515, 2003.
[ 4 6 ]S .C o l l i n s ,M .B o u v i e r ,M .A .B o l a n o w s k i ,M .G .C a r o n ,a n d
R. J. Lefkowitz, “cAMP stimulates transcription of the β2-
adrenergic receptor gene in response to short-term agonist
exposure,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 86, no. 13, pp. 4853–4857,
1989.
[ 4 7 ]S .C o l l i n s ,J .A l t s c h m i e d ,O .H e r b s m a n ,M .G .C a r o n ,P .L .
Mellon, and R. J. Lefkowitz, “A cAMP response element in the
β2-adrenergic receptor gene confers transcriptional autoregu-
lation by cAMP,” Journal of Biological Chemistry, vol. 265, no.
31, pp. 19330–19335, 1990.
[48] L. E. Cornett, F. C. Hiller, S. E. Jacobi, W. Cao, and D. W.
McGraw, “Identiﬁcation of a glucocorticoid response element
in the rat β2-adrenergic receptor gene,” Molecular Pharmacol-
ogy, vol. 54, no. 6, pp. 1016–1023, 1998.
[49] T. Bengtsson, B. Cannon, and J. Nedergaard, “Diﬀerential
adrenergic regulation of the gene expression of the β-adreno-
ceptor subtypes β1, β2 and β3 in brown adipocytes,” Biochemi-
cal Journal, vol. 347, no. 3, pp. 643–651, 2000.
[50] J. R. Hadcock and C. C. Malbon, “Regulation of β-adrenergic
receptors by “permissive” hormones: glucocorticoids increase
steady-state levels of receptor mRNA,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 85, no. 22, pp. 8415–8419, 1988.
[51] J. C. W. Mak, M. Nishikawa, H. Shirasaki, K. Miyayasu, and
P.J.Barnes,“Protectiveeﬀectsofaglucocorticoidondownreg-
ulation of pulmonary β2-adrenergic receptors in vivo,” Journal
of Clinical Investigation, vol. 96, no. 1, pp. 99–106, 1995.
[52] J. D. Port, L. Y. Huang, and C. C. Malbon, “β-Adrenergic ago-
nists that down-regulate receptor mRNA up-regulate a M(r)
35,000 protein(s) that selectively binds to β-adrenergic recep-
tor mRNAs,” Journal of Biological Chemistry, vol. 267, no. 33,
pp. 24103–24108, 1992.
[53] B. G. Tholanikunnel, J. G. Granneman, and C. C. Malbon,
“The M(r) 35,000 β-adrenergic receptor mRNA-binding pro-
tein binds transcripts of G-protein-linked receptors which
undergo agonist-induced destabilization,” Journal of Biological
Chemistry, vol. 270, no. 21, pp. 12787–12793, 1995.
[54] A. Pende, K. D. Tremmel, C. T. DeMaria et al., “Regulation
of the mRNA-binding protein AUF1 by activation of the β-
adrenergic receptor signal transduction pathway,” Journal of
Biological Chemistry, vol. 271, no. 14, pp. 8493–8501, 1996.
[55] B. C. Blaxall, A. C. Pellett, S. C. Wu, A. Pende, and J. D. Port,
“Puriﬁcation and characterization of β-adrenergic receptor
mRNA-binding proteins,” Journal of Biological Chemistry, vol.
275, no. 6, pp. 4290–4297, 2000.
[56] K. Baar and K. Esser, “Phosphorylation of p70(S6k) correlates
with increased skeletal muscle mass following resistance
exercise,” American Journal of Physiology, vol. 276, no. 1, pp.
C120–C127, 1999.
[57] P. A. Tesch and J. Karlsson, “Muscle ﬁber types and size in
trained and untrained muscles of elite athletes,” Journal of
Applied Physiology, vol. 59, no. 6, pp. 1716–1720, 1985.
[58] T. S. Wong and F. W. Booth, “Sekeletal muscle enlargement
with weight-lifting exercise by rats,” Journal of Applied Physi-
ology, vol. 65, no. 2, pp. 950–954, 1988.
[59] E. B. Colliander and P. A. Tesch, “Eﬀects of eccentric and
concentric muscle actions in resistance training,” Acta Physi-
ologica Scandinavica, vol. 140, no. 1, pp. 31–39, 1990.
[60] J. O. Holloszy, “Biochemical adaptations in muscle. Eﬀects
of exercise on mitochondrial oxygen uptake and respiratory
enzyme activity in skeletal muscle,” Journal of Biological
Chemistry, vol. 242, no. 9, pp. 2278–2282, 1967.
[ 6 1 ]J .O .H o l l o s z y ,L .B .O s c a i ,I .J .D o n ,a n dP .A .M o l ´ e,
“Mitochondrial citric acid cycle and related enzymes: adaptive
response to exercise,” Biochemical and Biophysical Research
Communications, vol. 40, no. 6, pp. 1368–1373, 1970.
[62] D.PetteandC.Heilmann,“Transformationofmorphological,
functional and metabolic properties of fast twitch muscle as
induced by long term electrical stimulation,” Basic Research in
Cardiology, vol. 72, no. 2-3, pp. 247–253, 1977.
[63] R. S. Staron, R. S. Hikida, and F. C. Hagerman, “Human
skeletal muscle ﬁber type adaptability to various workloads,”
Journal of Histochemistry and Cytochemistry,v o l .3 2 ,n o .2 ,p p .
146–152, 1984.
[64] R. Mounier, H. Cavali´ e, G. Lac, and E. Clottes, “Molecular
impact of clenbuterol and isometric strength training on rat
EDL muscles,” Pﬂugers Archiv European Journal of Physiology,
vol. 453, no. 4, pp. 497–507, 2007.
[65] G. S. Lynch, A. Hayes, S. P. Campbell, and D. A. Williams,
“Eﬀects of β2-agonist administration and exercise on contrac-
tile activation of skeletal muscle ﬁbers,” Journal of Applied
Physiology, vol. 81, no. 4, pp. 1610–1618, 1996.
[66] S. K. Powers, M. Wade, D. Criswell et al., “Role of beta-
adrenergic mechanisms in exercise training-induced meta-
bolic changes in respiratory and locomotor muscle,” Interna-
tional Journal of Sports Medicine, vol. 16, no. 1, pp. 13–18,
1995.
[67] C. E. Torgan, G. J. Etgen, J. T. Brozinick Jr., R. E. Wilcox, and
J. L. Ivy, “Interaction of aerobic exercise training and clen-
buterol: eﬀects on insulin-resistant muscle,” Journal of Applied
Physiology, vol. 75, no. 4, pp. 1471–1476, 1993.
[68] C. E. Torgan, J. T. Brozinick Jr., E. A. Banks, M. Y. Cortez, R. E.
Wilcox, and J. L. Ivy, “Exercise training and clenbuterol reduce
insulin resistance of obese Zucker rats,” American Journal of
Physiology, vol. 264, no. 3, pp. E373–E379, 1993.
[69] S. Miura, K. Kawanaka, Y. Kai et al., “An increase in murine
skeletal muscle peroxisome proliferator-activated receptor-γ
coactivator-1α (PGC-1α) mRNA in response to exercise is
mediated by β-adrenergic receptor activation,” Endocrinology,
vol. 148, no. 7, pp. 3441–3448, 2007.10 Journal of Biomedicine and Biotechnology
[70] C. Handschin, J. Rhee, J. Lin, P. T. Tarr, and B. M. Spiegelman,
“An autoregulatory loop controls peroxisome proliferator-
activated receptor γ coactivator 1α expression in muscle,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 12, pp. 7111–7116, 2003.
[71] T.Akimoto,S.C.Pohnert,P.Lietal.,“ExercisestimulatesPgc-
1α transcription in skeletal muscle through activation of the
p38 MAPK pathway,” Journal of Biological Chemistry, vol. 280,
no. 20, pp. 19587–19593, 2005.
[72] Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms con-
trolling mitochondrial biogenesis and respiration through the
thermogenic coactivator PGC-1,” Cell, vol. 98, no. 1, pp. 115–
124, 1999.
[73] J. Barbier, F. Rannou-Bekono, J. Marchais, P. M. Berthon,
P. Delamarche, and F. Carr´ e, “Eﬀect of training on β1β2β3
adrenergicandM2 muscarinicreceptorsinratheart,”Medicine
and Science in Sports and Exercise, vol. 36, no. 6, pp. 949–954,
2004.
[74] R. Stones, A. Natali, R. Billeter, S. Harrison, and E. White,
“Voluntary exercise-induced changes in β2-adrenoceptor sig-
nalling in rat ventricular myocytes,” Experimental Physiology,
vol. 93, no. 9, pp. 1065–1075, 2008.
[75] J. Ogasawara, M. Sanpei, N. Rahman et al., “β-Adrenergic
receptor traﬃcking by exercise in rat adipocytes: roles of
G-protein-coupled receptor kinase-2, β-arrestin-2, and the
ubiquitin-proteasome pathway,” FASEB Journal,v o l .2 0 ,n o .2 ,
pp. 350–352, 2006.
[76] T. Kizaki, T. Takemasa, T. Sakurai et al., “Adaptation of
macrophages to exercise training improves innate immunity,”
Biochemical and Biophysical Research Communications, vol.
372, no. 1, pp. 152–156, 2008.
[77] W. H. Martin, A. R. Coggan, R. J. Spina, and J. E. Saﬃtz,
“Eﬀects of ﬁber type and training on β-adrenoceptor density
inhumanskeletalmuscle,”AmericanJournalofPhysiology,vol.
257, no. 5, pp. E736–E742, 1989.
[78] R. P. Farrar, K. A. Monnin, D. E. Fordyce, and T. J. Walters,
“Uncouplingofchangesinskeletalmuscleβ-adrenergicrecep-
tor density and aerobic capacity during the aging process,”
Aging, vol. 9, no. 1-2, pp. 153–158, 1997.
[ 7 9 ]N .M .H e r r e r aJ r . ,A .N .Z i m m e r m a n ,D .D .D y k s t r a ,a n dL .
V. Thompson, “Clenbuterol in the prevention of muscle
atrophy: a study of hindlimb-unweighted rats,” Archives of
Physical Medicine and Rehabilitation, vol. 82, no. 7, pp. 930–
934, 2001.
[80] R. J. Zeman, R. Ludemann, and J. D. Etlinger, “Clenbuterol, a
β2-agonist, retards atrophy in denervated muscles,” American
Journal of Physiology, vol. 252, no. 1, pp. E152–E155, 1987.
[ 8 1 ] F .B e i t z e l ,P .G r e g o r e v i c ,J .G .R y a l l ,D .R .P l a n t ,M .N .S i l l e n c e ,
a n dG .S .L y n c h ,“ β2-adrenoceptor agonist fenoterol enhances
functional repair of regenerating rat skeletal muscle after
injury,” Journal of Applied Physiology, vol. 96, no. 4, pp. 1385–
1392, 2004.
[82] I. J. Smith, N. Alamdari, P. O’Neal, P. Gonnella, Z. Aversa, and
P. O. Hasselgren, “Sepsis increases the expression and activity
of the transcription factor Forkhead Box O 1 (FOXO1) in
skeletal muscle by a glucocorticoid-dependent mechanism,”
International Journal of Biochemistry and Cell Biology, vol. 42,
no. 5, pp. 701–711, 2010.
[ 8 3 ]W .Z h a o ,W .Q i n ,J .P a n ,Y .W u ,W .A .B a u m a n ,a n dC .C a r -
dozo, “Dependence of dexamethasone-induced Akt/FOXO1
signaling, upregulation of MAFbx, and protein catabolism
upontheglucocorticoidreceptor,”BiochemicalandBiophysical
Research Communications, vol. 378, no. 3, pp. 668–672, 2009.
[84] X. Sun, D. R. Fischer, T. A. Pritts, C. J. Wray, and P. O. Hassel-
gren, “Expression and binding activity of the glucocorticoid
receptor are upregulated in septic muscle,” American Journal
of Physiology, vol. 282, no. 2, pp. R509–R518, 2002.
[85] M. A. Pellegrino, G. D’Antona, S. Bortolotto et al., “Clen-
buterol antagonizes glucocorticoid-induced atrophy and ﬁbre
typetransformationinmice,”ExperimentalPhysiology,vol.89,
no. 1, pp. 89–100, 2004.